Updates are available Correction dated 2025-06-25
Click to view Correction: https://doi.org/10.1007/s11701-025-02452-9
-
Authors
Kelly, Susheian
Jindani, Rajika
Yanis, Sophia
Habboosh, Noor
Parmar, Priyanka
Quintero, Jorge-Humberto Rodriguez
Nobel, Tamar
Vimolratana, Marc
Chudgar, Neel
Stiles, Brendon https://orcid.org/0000-0002-4047-9787
-
Funding
Funding for this research was provided by:
NIH T32 (5T32CA200561-10)
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 18 March 2025
First Online: 22 May 2025
Change Date: 25 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11701-025-02452-9
Declarations
:
: Dr. Susheian Kelly, Sophia Yanis, Dr. Noor Habboosh, Dr. Priyanka Parmar, Dr. Jorge-Humberto Rodriguez Quintero, Dr. Tamar Nobel and Dr. Vimolratana has no conflict of interest to disclose. Dr. Rajika Jindani reports funding from NIH T32 grant (No. 5T32CA200561-10. Dr. Neel Chudgar has a consulting role at AstraZeneca. Dr. Brendon Stiles reports leadership at Verrica Pharmaceuticals; stock and other ownership interests in Pfizer, PPD, and Xalud Therapeutics; personal honoraria from AstraZeneca, Bristol Myers Squibb, Genentech, and Pfizer; consulting or advisor role at AstraZeneca, Gala Therapeutics, Medtronic, Arcus Biosciences, and Pfizer; research funding from Bristol Myers Squibb Foundation; patents, royalties, and other intellectual property related with a therapeutic antibody targeting ART1, an extracellular mono-ADP ribosyltransferase, for the treatment of cancer patent application filed; other relationship with Lung Cancer Research Foundation and Lungevity.
